Pharmacy Times – August 2017

Drug Interactions: Insights and Observations

Tamoxifen: New Developments

John R. Horn, PharmD, FCCP and Philip D. Hansten, PharmD

References:

1. Haque R, Shi J, Schottinger JE, Ahmed SA, Cheetham TC, Chung J, et al. Tamoxifen and antidepressant drug interaction among a cohort of 16 887 breast cancer survivors. J Natl Cancer Inst. 2016;108:

2. Donneyong MM, Bykov, K, Bosco-Levy P, Dong Y-H, Levin R, Gagne JJ. Risk of mortality wit concomitant use of tamoxifen and selective serotonin reuptake inhibitors: multi-database cohort study. BMJ. 2016;354:i5014 doi.org/10.1136/bmj.i5014

3. Kelley CM, Juurlink DN, Gomes T, Duong-Hua M, Pritchard KI, Austin PC, et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ. 2010:340:c693 doi:10.1136/bmj.c693

4. Goetz MP, Knox SK, Suman VJ, Rae JM, Safgren SI, Ames MM, et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat. 2007;101:113-121.

5. Chubak J, Boles EJA, Yu O, Buist DSM, Fujii M, Boudreau DM. Breast cancer recurrence in relation to antidepressant use. Cancer Causes Control. 2016;27:125-136.

6. Juurlink D. Revisiting the drug interaction between tamoxifen and SSRI antidepressants. BMJ. 2016;354:i5309 doi: 10.1136/bmj.i5309

7. Teft WA, Mansell SE, Kim RB. Endoxifen, the active metabolite of tamoxifen, is a substrate of the efflux transporter P-glycoprotein (multidrug resistance 1). Drug Metab Dispos. 2011;39:558-562.

8. Teh LK, Mohamed NI, Salleh MZ, Rohaizak M, Shahrun NS, Saladine JJ, et al. The risk of recurrence in breast cancer patients treated with tamoxifen: polymorphisms of CYP2D6 and ABCB1. AAPS J. 2011;14:52-59.

9. Binkhorst L, van Gelder T, Loos WJ, de Jongh FE, Hamberg P, Ghobadi Moghaddam-Helmantel IM, de Jonge E, Jager A, Seynaeve C, van Schaik RHN, Verweij J, Mathijssen RHJ. Effects of CYP induction by rifampicin on tamoxifen exposure. Clin Pharmacol Ther. 2012;92:62-67

10. Powers JL, Buys SS, Fletcher D, Melis R, Johnson-Davis KL, Lyon E, et al. Multigene and drug interaction approach for tamoxifen metabolite patterns reveals possible involvement of CYP2C9, CYP2C19, and ABCB1. J Clin Pharmacol. 2016;56:1570-1581